Related Experiment Video
Updated: Oct 20, 2025
08:45
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.4K
Integrated Approach to Identify Selective PTP1B Inhibitors Targeting the Allosteric Site
Ying Yang1, Lei Zhang1, Jinying Tian2
1Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P. R. China.
Journal of Chemical Information and Modeling
|September 15, 2021
Summary
Researchers identified novel allosteric inhibitors for Protein Tyrosine Phosphatase 1B (PTP1B), a challenging drug target. Compounds H3 and H9 show high selectivity, offering new avenues for developing specific PTP1B-targeting drugs.
Area of Science:
- Biochemistry
- Drug Discovery
- Computational Chemistry
Background:
- Protein Tyrosine Phosphatase 1B (PTP1B) is a difficult target for drug development due to its conserved catalytic site.
- Allosteric inhibition offers a promising strategy for achieving PTP1B specificity and bioavailability.
Purpose of the Study:
- To identify novel PTP1B inhibitors by targeting an allosteric site.
- To discover compounds with improved pharmacological profiles and selectivity over related phosphatases.
Main Methods:
- Hierarchical virtual screening of potential allosteric inhibitors.
- Molecular dynamics simulations and MM-GBSA calculations to analyze binding interactions.
- Assessing selectivity against homologous phosphatases like TCPTP and SHP2.
Main Results:
- Four potent PTP1B inhibitors (H1, H3, H7, H9) with unique structures were discovered.
- H3 and H9 exhibited significant selectivity for PTP1B over TCPTP and SHP2.
- Key residues (Phe280, Phe196, Leu192, Asn193) were identified as crucial for allosteric inhibition and selectivity.
Conclusions:
- The study identified novel allosteric inhibitors for PTP1B, expanding structural diversity.
- The findings provide a foundation for designing future PTP1B allosteric inhibitors with enhanced selectivity and pharmacological properties.
Related Concept Videos
01:19Allosteric Proteins-ATCase
6.0K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.0K
00:49Ligand Binding and Linkage
5.1K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.1K